Recently, immune checkpoint blocker therapy, particularly antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway, has sparked a boom in systemic treatment aimed at improving the tumor response and survival of HCC patients (6–12). This evidence concerns the gene PDCD1 and neoplasm.